Discover the Benefits of Anti-IL13 Antibody for Your Research Needs

Alpha Lifetech Incorporation proudly presents our cutting-edge anti-il13 antibody, designed to advance research in immunology and therapeutic development. Interleukin 13 (IL-1plays a crucial role in the regulation of immune responses and is often implicated in various allergic and inflammatory conditions. Our high-affinity anti-IL13 antibody is meticulously engineered to provide sensitive and specific binding, allowing for enhanced detection and quantification of IL-13 in various biological samples, This product is ideal for applications such as ELISA, Western blotting, and immunohistochemistry, making it a versatile tool for researchers tackling respiratory diseases, asthma, and other IL-13 mediated disorders. With rigorous quality control standards, our anti-IL13 antibody ensures reproducible results and reliable performance. By choosing Alpha Lifetech's anti-IL13 antibody, you are equipping your laboratory with a powerful resource to unlock new insights and foster breakthroughs in understanding immune regulation. Explore the potential of our innovative products and contribute to the future of biomedical research

Hot Selling Product

ADT1126-Cendakimab Biosimilar-(IL13)-Research Biosimilar Antibody

ADT1008-Abrezekimab Biosimilar (IL13)-Research Biosimilar Antibody

ADT1743-Human Anti-PD-1xCTLA-4 Bispecific Antibody

ADT1746-Human Anti-CD3ExBCMA Bispecific Antibody

ADT1748-Human Anti-IGF1RxHer3 Bispecific Antibody

ADT1749-Human Anti-CD3ExCD20 Bispecific Antibody

How To Select anti-il13 antibody Delivers Unmatched Quality Pioneers in the Field

Selecting the right anti-IL13 antibody is crucial for researchers aiming to understand and manipulate immune responses. As a leader in the field, Alpha Lifetech Inc. offers unmatched quality in antibodies, backed by our team of scientists with extensive experience in membrane protein production, Nanobody discovery, and monoclonal development. Our commitment to quality is evidenced by our extensive catalog, featuring nearly 10,000 high-quality reagents including cytokines and drug target antibodies. When choosing an anti-IL13 antibody, it’s essential to consider specificity, sensitivity, and data supporting its application. Our antibodies are meticulously developed and validated, ensuring reliable performance in various applications, including ELISA, Western Blot, and immunohistochemistry. Furthermore, our scientists are available to guide you through the selection process, ensuring that you find the perfect match for your research needs. By partnering with Alpha Lifetech Inc., you gain access to pioneering products designed to elevate your research. Our focus on innovation and excellence ensures that you receive not only high-quality reagents but also unmatched customer support to help you achieve your scientific goals. Explore our range today and experience the difference that quality makes in your research endeavors.

How To Select anti-il13 antibody Delivers Unmatched Quality Pioneers in the Field

Feature	Description	Quality Rating	Applications	Availability
Specificity	Highly specific to IL-13 protein	4.8/5	Western Blot, ELISA	In Stock
Purity	>95% pure by SDS-PAGE	4.7/5	Immunohistochemistry	Pre-Order
Conjugation	Available with a variety of dyes	4.9/5	Flow Cytometry	Limited Stock
Cross-reactivity	Minimal cross-reactivity with IL-4	4.6/5	Neutralization Studies	In Stock
Source	Mouse monoclonal	4.8/5	Therapeutic Potential	Special Order

Analysis of Binding Affinity of Anti-IL13 Antibodies Over Time

This chart illustrates the trend in binding affinity (KD) of anti-IL13 antibodies from the year 2019 to 2023. Binding affinity is a critical parameter that reflects the strength of the interaction between an antibody and its target antigen, in this case, the IL13 molecule. The data shows a consistent improvement in binding affinity over the years, indicating advancements in antibody engineering and development techniques. In 2019, the binding affinity was at 0.5 KD, and it has gradually decreased to 0.25 KD by 2023. This decrease signifies an enhancement in the antibody's efficacy and selectivity towards IL13, which is pivotal for therapeutic applications targeting allergic diseases and asthma. Understanding these trends is essential for researchers looking to select high-quality anti-IL13 antibodies for their projects, as improved binding affinity correlates with better potential outcomes in experimental and clinical settings.